Contact
searchSearch
HMP Global

Pulmonary Arterial Hypertension Topic Center

News
Adding Selexipag to Standard Therapy Reduces Hospitalizations in Patients With Pulmonary Arterial Hypertension
12/16/2024
Adding oral selexipag to double oral therapy (DOT) within 6 months significantly reduces the risk of hospitalization and disease progression in patients with pulmonary arterial hypertension (PAH).
Adding oral selexipag to double oral therapy (DOT) within 6 months significantly reduces the risk of hospitalization and disease progression in patients with pulmonary arterial hypertension (PAH).
Adding oral selexipag to double...
12/16/2024
First Report Managed Care
News
Machine Learning Advances Revolutionize Pulmonary Arterial Hypertension Diagnosis
12/09/2024
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
Machine learning techniques such...
12/09/2024
First Report Managed Care
News
Sex Differences in Survival Among Patients With Pulmonary Arterial Hypertension
11/22/2024
A recent study investigated the “sex paradox” in pulmonary arterial hypertension, which highlights better survival outcomes in women despite more severe disease presentation.
A recent study investigated the “sex paradox” in pulmonary arterial hypertension, which highlights better survival outcomes in women despite more severe disease presentation.
A recent study investigated the...
11/22/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
The Impact of Cardiovascular and Lung Comorbidities on Patients With Pulmonary Arterial Hypertension
10/29/2024
This systematic review explores the impact of cardiovascular and lung comorbidities on pulmonary arterial hypertension patients, revealing the need for tailored management for this high-risk population.
This systematic review explores the impact of cardiovascular and lung comorbidities on pulmonary arterial hypertension patients, revealing the need for tailored management for this high-risk population.
This systematic review explores...
10/29/2024
First Report Managed Care
News
Riociguat Emerges as Key Alternative for Nonresponders to Traditional Treatments in Pulmonary Arterial Hypertension
10/25/2024
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Recent advancements in the...
10/25/2024
First Report Managed Care
Evolving Histopathologic and Clinical Profiles in Idiopathic Pulmonary Arterial Hypertension
10/14/2024
Study findings suggest that a significant proportion of modern idiopathic pulmonary arterial hypertension (IPAH) cases may not exhibit the classic plexiform vasculopathy seen in earlier descriptions of the disease, according to researchers.
Study findings suggest that a significant proportion of modern idiopathic pulmonary arterial hypertension (IPAH) cases may not exhibit the classic plexiform vasculopathy seen in earlier descriptions of the disease, according to researchers.
Study findings suggest that a...
10/14/2024
First Report Managed Care
News
Projected Growth of the Pulmonary Arterial Hypertension Drugs Market
10/07/2024
The pulmonary arterial hypertension drug market is projected to grow to $11.6 billion by 2032, driven by an increase in pulmonary disorders, advancements in treatment options, and greater awareness of the condition.
The pulmonary arterial hypertension drug market is projected to grow to $11.6 billion by 2032, driven by an increase in pulmonary disorders, advancements in treatment options, and greater awareness of the condition.
The pulmonary arterial...
10/07/2024
First Report Managed Care
Interview
Key Pharmaceutical Pipeline Developments: Insights from Industry Experts
05/29/2024
Leslie Fish, RPh, Senior Vice President of Clinical Pharmacy, IPD Analytics, LLC
Jeffrey Casberg, MS, RPh, IPD, Vice President of Clinical Pharmacy, IPD Analytics, LLC
Learn about promising drugs currently in the pharmaceutical pipeline and the impact of FDA interventions from presenters at AMCP 2024.
Learn about promising drugs currently in the pharmaceutical pipeline and the impact of FDA interventions from presenters at AMCP 2024.
Learn about promising drugs...
05/29/2024
First Report Managed Care
Sarah Emond
Interview
Improving Patient Engagement in Managed Care Pharmacy Through Collaboration
05/21/2024
Sarah Emond, MPP, President and Chief Executive Officer, ICER
Patient perspectives play a crucial role in shaping healthcare decisions, and AMCP 2024 session speaker Sarah Emond discusses the importance of patient engagement in drug value assessments within the managed care framework, providing examples...
Patient perspectives play a crucial role in shaping healthcare decisions, and AMCP 2024 session speaker Sarah Emond discusses the importance of patient engagement in drug value assessments within the managed care framework, providing examples...
Patient perspectives play a...
05/21/2024
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Interview
FRMC Volume 22, Issue 1

Current Issue

March 2025
Volume 22
Issue 1
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use